Market-Moving News for April 9th
$ACRV
$LASE
$VVOS
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Machinery/Components
Miscellaneous
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 5/5/2025 | $6.00 | Overweight | Piper Sandler | |
| 1/31/2025 | Overweight | KeyBanc Capital Markets | ||
| 9/16/2024 | $16.00 | Neutral → Buy | Ladenburg Thalmann | |
| 4/29/2024 | Buy → Neutral | Ladenburg Thalmann | ||
| 3/1/2024 | $14.00 | Mkt Outperform | JMP Securities | |
| 12/15/2023 | $17.00 → $12.00 | Buy | Jefferies | |
| 10/5/2023 | Buy | Maxim Group | ||
| 6/2/2023 | $25.00 | Outperform | Oppenheimer |
424B4 - Laser Photonics Corp (0001807887) (Filer)
EFFECT - Laser Photonics Corp (0001807887) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC., Jan. 28, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – As the global oncology clinical trials market surges toward a projected $25.61 billion valuation by 2035[1], a structural rotation is favoring 'registration-ready' platforms that demonstrate exceptional efficacy and pivotal-trial alignment with 2026's evolving FDA regulatory frameworks[2]. Investors are increasingly prioritizing late-stage and newly commercial companies poised for rapid maturation as sector fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ:ONCY), BioNTech (NASDAQ:BNTX), MAIA Biotechnology (NYSE-A: MAIA)
WATERTOWN, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced a presentation at the upcoming ESGO 27th Annual Congress, being held in Copenhagen, Denmark, February 26-28, 2026. "We are very excited that Dr. Konstantinopoulos will be
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00
KeyBanc Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Overweight
Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a press release at 7:30 a.m. ET, and conference call and webcast at 8:30 a.m. ET, both on Thu
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026. Topics will include: Updated interim ACR-368
LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e
Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv
Laser Photonics Corporation (NASDAQ: LASE) (LPC), a leading global developer of laser systems for cleaning and other material processing applications, announced today that it has appointed John T. Armstrong as its new Executive Vice President. Prior to joining Laser Photonics, Armstrong served as a Vice President for Astronics Test Systems (ATS), a subsidiary of Astronics Corporation, a leading supplier of advanced technologies and products to the global aerospace, defense and other mission-critical industries. Previously, he served as a Senior Manager for Boeing, providing leadership and HR support for 10,000+ employees nationwide within a division that generated $4.5B+ in revenue. Earli
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
